Annual SG&A
$6.88 M
-$1.22 M-15.02%
31 December 2023
Summary:
Corvus Pharmaceuticals annual selling, general & administrative expenses is currently $6.88 million, with the most recent change of -$1.22 million (-15.02%) on 31 December 2023. During the last 3 years, it has fallen by -$5.05 million (-42.32%). CRVS annual SG&A is now -42.32% below its all-time high of $11.93 million, reached on 31 December 2020.CRVS Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$2.03 M
+$212.00 K+11.64%
30 September 2024
Summary:
Corvus Pharmaceuticals quarterly selling, general & administrative expenses is currently $2.03 million, with the most recent change of +$212.00 thousand (+11.64%) on 30 September 2024. Over the past year, it has increased by +$438.00 thousand (+27.46%). CRVS quarterly SG&A is now -37.50% below its all-time high of $3.25 million, reached on 31 March 2021.CRVS Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$1.40 B
-$56.83 M-4.22%
30 September 2024
Summary:
Corvus Pharmaceuticals TTM selling, general & administrative expenses is currently -$1.40 billion, with the most recent change of -$56.83 million (-4.22%) on 30 September 2024. Over the past year, it has dropped by -$1.41 billion (-20712.06%). CRVS TTM SG&A is now -5417.98% below its all-time high of $12.08 million, reached on 31 March 2021.CRVS TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CRVS Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -15.0% | +27.5% | -10000.0% |
| 3 y3 years | -42.3% | -1.1% | -10000.0% |
| 5 y5 years | -35.3% | -19.2% | -10000.0% |
CRVS Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -42.3% | at low | -12.1% | +28.2% | -46.1% | at low |
| 5 y | 5 years | -42.3% | at low | -37.5% | +28.2% | -86.4% | at low |
| alltime | all time | -42.3% | +184.6% | -37.5% | +601.0% | -5418.0% | at low |
Corvus Pharmaceuticals Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $2.03 M(+11.6%) | $7.68 M(+6.0%) |
| June 2024 | - | $1.82 M(-16.4%) | $7.25 M(+2.4%) |
| Mar 2024 | - | $2.18 M(+31.8%) | $7.08 M(+2.9%) |
| Dec 2023 | $6.88 M(-15.0%) | $1.65 M(+3.6%) | $6.88 M(+1.0%) |
| Sept 2023 | - | $1.59 M(-3.6%) | $6.82 M(-7.0%) |
| June 2023 | - | $1.65 M(-16.5%) | $7.33 M(-5.6%) |
| Mar 2023 | - | $1.98 M(+24.8%) | $7.76 M(-4.1%) |
| Dec 2022 | $8.10 M(-14.9%) | $1.59 M(-24.8%) | $8.10 M(-5.1%) |
| Sept 2022 | - | $2.11 M(+0.9%) | $8.53 M(+0.6%) |
| June 2022 | - | $2.09 M(-9.6%) | $8.48 M(-1.1%) |
| Mar 2022 | - | $2.31 M(+14.4%) | $8.57 M(-9.9%) |
| Dec 2021 | $9.52 M(-20.2%) | $2.02 M(-1.7%) | $9.52 M(-6.5%) |
| Sept 2021 | - | $2.06 M(-5.9%) | $10.18 M(-10.3%) |
| June 2021 | - | $2.18 M(-32.9%) | $11.35 M(-6.0%) |
| Mar 2021 | - | $3.25 M(+21.0%) | $12.08 M(+1.2%) |
| Dec 2020 | $11.93 M(+9.7%) | $2.69 M(-16.7%) | $11.93 M(+1.4%) |
| Sept 2020 | - | $3.23 M(+10.9%) | $11.76 M(+6.4%) |
| June 2020 | - | $2.91 M(-6.3%) | $11.05 M(-0.4%) |
| Mar 2020 | - | $3.11 M(+23.3%) | $11.10 M(+2.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2019 | $10.88 M(+2.3%) | $2.52 M(+0.1%) | $10.88 M(-2.3%) |
| Sept 2019 | - | $2.52 M(-14.9%) | $11.14 M(-2.3%) |
| June 2019 | - | $2.96 M(+2.4%) | $11.39 M(+3.8%) |
| Mar 2019 | - | $2.89 M(+3.9%) | $10.98 M(+3.2%) |
| Dec 2018 | $10.64 M(+4.1%) | $2.78 M(+0.1%) | $10.64 M(+2.7%) |
| Sept 2018 | - | $2.77 M(+9.1%) | $10.36 M(+5.8%) |
| June 2018 | - | $2.54 M(+0.1%) | $9.80 M(-2.4%) |
| Mar 2018 | - | $2.54 M(+1.6%) | $10.04 M(-1.8%) |
| Dec 2017 | $10.22 M(+34.1%) | $2.50 M(+13.1%) | $10.22 M(+3.9%) |
| Sept 2017 | - | $2.21 M(-20.7%) | $9.84 M(-5.4%) |
| June 2017 | - | $2.79 M(+2.5%) | $10.39 M(+11.6%) |
| Mar 2017 | - | $2.72 M(+28.4%) | $9.31 M(+22.2%) |
| Dec 2016 | $7.62 M(+215.1%) | $2.12 M(-23.5%) | $7.62 M(+13.8%) |
| Sept 2016 | - | $2.77 M(+62.3%) | $6.70 M(+47.7%) |
| June 2016 | - | $1.71 M(+65.8%) | $4.54 M(+43.7%) |
| Mar 2016 | - | $1.03 M(-13.9%) | $3.16 M(+30.6%) |
| Dec 2015 | $2.42 M | $1.20 M(+97.2%) | $2.42 M(+97.7%) |
| Sept 2015 | - | $606.00 K(+85.3%) | $1.22 M(+98.2%) |
| June 2015 | - | $327.00 K(+12.8%) | $617.00 K(+112.8%) |
| Mar 2015 | - | $290.00 K | $290.00 K |
FAQ
- What is Corvus Pharmaceuticals annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Corvus Pharmaceuticals?
- What is Corvus Pharmaceuticals annual SG&A year-on-year change?
- What is Corvus Pharmaceuticals quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Corvus Pharmaceuticals?
- What is Corvus Pharmaceuticals quarterly SG&A year-on-year change?
- What is Corvus Pharmaceuticals TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Corvus Pharmaceuticals?
- What is Corvus Pharmaceuticals TTM SG&A year-on-year change?
What is Corvus Pharmaceuticals annual selling, general & administrative expenses?
The current annual SG&A of CRVS is $6.88 M
What is the all time high annual SG&A for Corvus Pharmaceuticals?
Corvus Pharmaceuticals all-time high annual selling, general & administrative expenses is $11.93 M
What is Corvus Pharmaceuticals annual SG&A year-on-year change?
Over the past year, CRVS annual selling, general & administrative expenses has changed by -$1.22 M (-15.02%)
What is Corvus Pharmaceuticals quarterly selling, general & administrative expenses?
The current quarterly SG&A of CRVS is $2.03 M
What is the all time high quarterly SG&A for Corvus Pharmaceuticals?
Corvus Pharmaceuticals all-time high quarterly selling, general & administrative expenses is $3.25 M
What is Corvus Pharmaceuticals quarterly SG&A year-on-year change?
Over the past year, CRVS quarterly selling, general & administrative expenses has changed by +$438.00 K (+27.46%)
What is Corvus Pharmaceuticals TTM selling, general & administrative expenses?
The current TTM SG&A of CRVS is -$1.40 B
What is the all time high TTM SG&A for Corvus Pharmaceuticals?
Corvus Pharmaceuticals all-time high TTM selling, general & administrative expenses is $12.08 M
What is Corvus Pharmaceuticals TTM SG&A year-on-year change?
Over the past year, CRVS TTM selling, general & administrative expenses has changed by -$1.41 B (-20712.06%)